Clinical trials
Locally Advanced Cervical Carcinoma clinical trials
Below are recruiting locally advanced cervical carcinoma clinical trials, each written for real people, not researchers. We’re tracking 298 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06477991Recruiting
No surgery after immunotherapy for MSI-H colorectal cancer
This trial is studying whether some people with a specific type of advanced colorectal cancer (MSI-H/dMMR) might be able to skip surgery after immunotherapy. Doctors will use a blood test (MRD monitoring) to track the cancer, and then decide whether to keep an eye on it or operate.
Kunming, YunnanAges 18–75 - NCT05940896RecruitingPhase 1
HER2-targeted drug with radiation for non-surgical solid cancers
This Phase 1 study tests a HER2-targeted antibody drug (RC48-ADC) given with radiation in people with locally advanced solid tumors that cannot be removed by surgery. It aims to find a safe way to use the treatment and see how well it works in cancers that have HER2 protein on their cells.
Jinan, ShandongAges 18 years+ - NCT07699939RecruitingPhase 2
Perioperative immunotherapy plus chemo for advanced gastric cancer
This trial tests whether adding the immunotherapy drug HLX10 (serplulimab) to standard chemotherapy (S-1 plus oxaliplatin) before and after surgery can improve outcomes for patients with advanced gastric or gastroesophageal junction cancer that has a high level of PD-L1 protein.
Chiba, ChibaAges 18–80 - NCT03671252RecruitingPhase 3
Chemotherapy before surgery for rectal cancer vs chemo with radiation
This Phase 3 trial compares two treatment plans given before rectal surgery. It tests whether stronger chemotherapy alone works better than chemotherapy pills plus long-term radiation to improve outcomes for locally advanced rectal cancer.
Guangzhou, GuangdongAges 18–75 - NCT04165772RecruitingPhase 2
Dostarlimab for locally advanced mismatch-repair deficient solid tumors
This Phase 2 trial studies dostarlimab (an immune therapy that targets PD-1) given before surgery or other initial treatment. It aims to shrink certain locally advanced cancers that have mismatch repair deficiency, potentially making treatment easier and improving outcomes.
Hartford, ConnecticutAges 18 years+ - NCT04383119RecruitingPhase 2
Study for advanced leiomyosarcoma after prior chemo
This Phase 2 trial studies how well gemcitabine or trabectedin works for people with leiomyosarcoma that cannot be fully removed or has spread. It’s for tumors that have grown or worsened despite prior standard chemotherapy.
Bologna, BOAges 18 years+ - NCT04495088RecruitingPhase 3
Before vs after chemotherapy for locally advanced rectal cancer
This Phase 3 study compares giving chemotherapy before rectal surgery versus giving it after surgery, using a tailored plan based on your risk. The goal is to see which timing helps more people with locally advanced rectal cancer stay cancer-free and live longer.
MannheimAges 18 years+ - NCT05148767RecruitingPhase 4
UGT1A1-guided irinotecan for locally advanced rectal cancer
This trial studies whether adjusting irinotecan treatment based on a person’s UGT1A1 gene test can improve outcomes for locally advanced rectal cancer. It focuses on people who are about to start (or continue) chemoradiation and do not have cancer spread to distant organs.
Hangzhou, ZhejiangAges 18–75 - NCT05184803RecruitingPhase 2
Pre-surgery chemo for advanced stomach cancer with lymph spread
This Phase 2 study tests a combination chemotherapy regimen given before surgery for stomach cancer that cannot be fully removed (unresectable), including spread to lymph nodes. The goal is to shrink the cancer and improve control with a well-known set of medicines given in a specific order.
Seoul, SeoulAges 19 years+ - NCT05378204Recruiting
Testing DNA repair marker for PARP inhibitor resistance
This study looks at specific DNA “damage repair” proteins as a marker to understand why some BRCA-mutated breast cancers may resist PARP inhibitor treatment. Your biopsy (or existing biopsy) helps researchers study whether these lab markers relate to how well PARP inhibitors work.
BordeauxAges 18 years+ - NCT05388773RecruitingPhase 2
Surgery then lower-dose radiation for p16+ throat cancer
This Phase 2 study tests whether removing the tumor through the mouth, followed by a reduced course of radiation, can control HPV-related (p16+) oropharynx throat cancer. It may help reduce treatment intensity after surgery, while still aiming to keep the cancer from coming back.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT05582499RecruitingPhase 2
Neoadjuvant treatment study for certain breast cancers
This Phase 2 study tests a “precision platform” approach—treatment before surgery—based on specific test results from your breast tumor. It may help determine whether the treatment plan works better for people with particular breast cancer subtypes and healthy organ function.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT05672524RecruitingPhase 2
Tucatinib plus trastuzumab for HER2-positive rectal cancer
This Phase 2 study tests whether tucatinib combined with trastuzumab can slow or shrink rectal cancer that is HER2-positive and has certain genetic tumor features. If you qualify, you may benefit from a targeted treatment approach aimed at the HER2 pathway.
Basking Ridge, New JerseyAges 18 years+ - NCT05758389RecruitingPhase 2
Immunotherapy plus chemo for locally advanced head and neck cancer
This Phase 2 study tests whether tislelizumab (an immunotherapy) combined with chemotherapy works better for locally advanced head and neck squamous cell cancer. It aims to improve cancer control when the tumor is large and has not spread to distant organs.
Nanjing, JiangsuAges 18–75 - NCT05772481Recruiting
PET-MRI scan test for rectal cancer after pre-surgery treatment
This study looks at whether a special scan called PET-MRI can better show how rectal cancer responds to treatment given before surgery. If it works well, it could help doctors plan the right next steps after chemoradiotherapy.
StrasbourgAges 18–75 - NCT05806060RecruitingPhase 3
Targeted first treatment for a rare TNBC subtype with spread
This Phase 3 trial tests a more precise treatment strategy for a specific rare type of triple-negative breast cancer (TNBC) called the BLIS subtype. It’s for people whose cancer has spread or cannot be fully removed and who have not had chemo or targeted therapy for metastatic TNBC yet.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT05965531RecruitingPhase 2
TAS-102 plus radiation before surgery for rectal cancer
This trial studies whether adding TAS-102 (a chemotherapy medicine) to radiation given before treatment improves outcomes for certain locally advanced rectal cancers. It may help by trying to shrink the tumor before the next steps of care.
Guangzhou, GuangdongAges 18–70 - NCT06026943Recruiting
Alpha radiation therapy for locally advanced pancreatic cancer
This trial tests a new treatment that uses tiny alpha radiation sources placed directly into the tumor to destroy cancer cells. It is for people with pancreatic cancer that has not spread but cannot be removed surgically, and who have already tried at least one type of chemotherapy or cannot take more chemo.
VeronaAges 18–120 - NCT06207981RecruitingPhase 3
Comparing two treatment plans for advanced anal cancer
This trial tests if giving chemotherapy before standard chemoradiation works better than standard chemoradiation alone for people with locally advanced anal cancer that has not spread. It aims to improve treatment outcomes.
AgenAges 18 years+ - NCT06276283RecruitingPhase 2
DZD9008 plus bevacizumab for EGFR-mutated advanced lung cancer
This trial tests a new targeted therapy (DZD9008) combined with a drug that blocks blood vessel growth (bevacizumab) for people with a specific type of advanced lung cancer (EGFR mutation). The goal is to see if this combination works better than current treatments.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06368141RecruitingPhase 2
Chemo plus immunotherapy before surgery for colon cancer
This trial tests whether giving chemotherapy followed by an immunotherapy drug (a checkpoint inhibitor) before surgery helps shrink locally advanced colon cancer. It is for people with a specific tumor type (MSS and RAS mutation) who have not had prior treatment.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06475417RecruitingPhase 2
Adebrelimab plus chemo before stomach cancer surgery
This trial tests a combination of chemotherapy (DOS) plus an immunotherapy drug (Adebrelimab) given before surgery for people with locally advanced stomach or gastroesophageal junction cancer. The goal is to see if the treatment shrinks the tumor and improves outcomes.
Xi'an, ShannxiAges 18–75 - NCT06524167Recruiting
Radiation therapy after surgery for advanced thyroid cancer
This study looks at whether adding radiation therapy after surgery can help people with thyroid cancer that is at high risk of coming back. It includes different types of thyroid cancer, like differentiated and medullary types.
ShanghaiAges 14–80 - NCT06558981RecruitingPhase 3
Radiation therapy after thyroid surgery for high-risk cancer
This trial is testing whether giving radiation therapy after thyroid surgery can help destroy any leftover cancer cells in people with high-risk differentiated thyroid cancer. It is for those who had surgery but some cancer was still left behind.
ShanghaiAges 14–80
Hear when a new Locally Advanced Cervical Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for locally advanced cervical carcinoma?
- Yes. Clin2 currently lists 298 recruiting locally advanced cervical carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a locally advanced cervical carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a locally advanced cervical carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Locally Advanced Cervical Cancer
- Locally Advanced Rectal Carcinoma
- Locally Advanced Head and Neck Squamous Cell Carcinoma
- Locally Advanced Nasopharyngeal Carcinoma
- Locally Advanced Esophageal Squamous Cell Carcinoma
- Locally Advanced Hepatocellular Carcinoma
- Locally Advanced Lung Non-Small Cell Carcinoma
- Locally Advanced Urothelial Carcinoma
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.